Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ARNT | P27540 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4211542 | 1.00 | CA1 (0.46) | CA1CA2CA9ALDH1A1USP2 | |
| SCHEMBL495977 | 1.00 | CA1 (0.46) | CA1CA2CA9ALDH1A1USP2 | |
| SCHEMBL5990289 | 0.87 | CA1 (0.59) | CA1CA2CA9ALDH1A1USP2 | |
| SCHEMBL11745911 | 0.82 | CA1 (0.48) | CA1CA2CA9MAPTCA12 | |
| SCHEMBL4204044 | 0.81 | CA1 (0.43) | CA1CA2CA9ALDH1A1USP2 | |
| SCHEMBL4204052 | 0.81 | CA1 (0.43) | CA1CA2CA9ALDH1A1USP2 | |
| SCHEMBL7302948 | 0.80 | CA1 (0.46) | CA1CA2CA9ALDH1A1USP2 | |
| SCHEMBL15892763 | 0.78 | CA1 (0.50) | CA1CA2CA9ALDH1A1USP2 | |
| SCHEMBL2591059 | 0.78 | CA1 (0.77) | CA1CA2CA9CA12CA7 | |
| SCHEMBL15607878 | 0.78 | CA1 (0.50) | CA1CA2CA9ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202968-A1 | PROCESS FOR PREPARING 2-METHYL-N-(2' -METHYLBUTYL)BUTANAMIDE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-29 | — | — | US | disclosed |
| US-11629119-B2 | Process for preparing 2-methyl-N-(2′-methylbutyl)butanamide | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-04-18 | — | — | US | disclosed |
| US-20220411363-A1 | PROCESS FOR PREPARING 2-METHYL-N-(2' -METHYLBUTYL)BUTANAMIDE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-4101840-A1 | PROCESS FOR PREPARING 2-METHYL-N- (2' -METHYLBUTYL) BUTANAMIDE | Shin-Etsu Chemical Co., Ltd. (JP) | 2022-12-14 | — | — | EP | disclosed |
| CN-110325531-A | Benzsulfamide and its purposes as therapeutic agent | 泽农医药公司 | 2019-10-11 | — | — | CN | disclosed |
| CN-106715438-B | Triazolopyrazine ketone as PDE1 inhibitor | H.隆德贝克有限公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-106715438-A | Triazolopyrazinones as PDE1 inhibitors | H.隆德贝克有限公司 | 2017-05-24 | — | — | CN | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| WO-1998008839-A1 | COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED THIOPHENE LIBRARIES | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| WO-1998008813-A1 | COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED PYRROLIDINE LIBRARIES | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0816310-A2 | Scavenger assisted combinatorial process for preparing libraries of tertiary amine compounds | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997026300-A1 | COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED INDANE LIBRARIES | ELI LILLY AND COMPANY (US) | 1997-07-24 | — | — | WO | disclosed |
| US-5488162-A | Process for preparing o-alkylhydroxylamine salts without the isolation of intermediates | EASTMAN CHEMICAL COMPANY | 1996-01-30 | — | — | US | disclosed |
| WO-1995018788-A1 | PROCESS FOR PREPARING O-ALKYLHYDROXYLAMINE SALTS WITHOUT THE ISOLATION OF INTERMEDIATES | EASTMAN CHEMICAL COMPANY (US) | 1995-07-13 | — | — | WO | disclosed |
| US-5389290-A | Ferroelectric liquid crystalline materials | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-02-14 | — | — | US | disclosed |
| US-5089168-A | Stable ferroelectric liquid crystals | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-02-18 | — | — | US | disclosed |
| US-4834904-A | FERROELECTRIC LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-05-30 | — | — | US | disclosed |
| US-4776973-A | LIQUID CRYSTAL ELECTROOPTICS DISPLAY DEVICE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411363-A1 | PROCESS FOR PREPARING 2-METHYL-N-(2' -METHYLBUTYL)BUTANAMIDE | ALKBH5, ALKBH2, ADRB2 | CA1 3730/4885CA2 2532/4885CA9 2179/4885 |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | CA1 3179/4885CA2 688/4885CA9 3026/4885 |
| US-11629119-B2 | Process for preparing 2-methyl-N-(2′-methylbutyl)butanamide | ALKBH5, ALKBH2, ADRB2 | CA1 3776/4885CA2 2584/4885CA9 2174/4885 |
| US-20230202968-A1 | PROCESS FOR PREPARING 2-METHYL-N-(2' -METHYLBUTYL)BUTANAMIDE | ALKBH5, ALKBH2, ADRB2 | CA1 3730/4885CA2 2532/4885CA9 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.